Physician profile
Katie E Reid
NPI 1669765111
$1,415.16
in general payments reported to CMS, 2019-2025
14 companies · $39.16 in 2025
The $39.16 reported for 2025 was less than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $418 · 2020: $14.93 · 2021: $349 · 2022: $293 · 2023: $301 · 2025: $39.16.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $341.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $340.53 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $298.29 | 2019-2022 | |
| Novo Nordisk INC | $285.27 | 2021-2023 | Ozempic, Rybelsus |
| Abbvie INC. | $257.04 | 2023 | |
| Astrazeneca Pharmaceuticals LP | $130.09 | 2019 | |
| Lilly USA, LLC | $93.79 | 2019 | |
| Eisai INC. | $68.31 | 2021-2022 | |
| Abbott Laboratories | $64.75 | 2022-2025 | Freestyle Libre 2 |
| Merck Sharp & Dohme LLC | $54.40 | 2019-2022 | |
| Novartis Pharmaceuticals Corporation | $47.88 | 2022 | |
| Almatica Pharma LLC | $33.26 | 2021-2022 | |
| Glaxosmithkline, LLC. | $27.46 | 2022-2025 | Shingrix |
| Allergan, INC. | $20.66 | 2019 | |
| Biohaven Pharmaceutical Holding Company LTD. | $19.03 | 2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $14.93 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Katie Reid listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.